scholarly journals Determinants of Cancer-specific Quality of Life in Veteran Lung Cancer Survivors Eligible for Long-Term Cure

2019 ◽  
Author(s):  
Duc Ha ◽  
Andrew L. Ries ◽  
Jeffrey J. Swigris

AbstractRationale/ObjectiveQuality of life (QoL) is an important issue in lung cancer survivors. We aimed to identify determinants of QoL in lung cancer survivors eligible for long-term cure.MethodsWe performed an exploratory analysis of a cross-sectional study of consecutive lung cancer survivors who completed curative-intent treatment ≥1 month previously. Variables tested included demographic, clinical, physiologic, and symptom-specific patient-reported outcome measures. We defined the primary outcome as a previously-validated cancer-specific QoL measure – the European Organization for Research and Treatment of Cancer QoL Questionnaire Core 30 (C30) summary score. We also verified our findings with the C30 global health status/QoL subscale and a summated score of lung cancer-specific QoL from the EORTC-Lung Cancer Module 13.ResultsIn 75 enrolled participants, measures of fatigue, depression, sleep difficulties, and dyspnea were statistically significant determinants of the C30 summary score in multivariable linear regression analyses. Together, these four symptoms accounted for approximately 85% of the variance in cancer-specific QoL (p<0.001). When we verified our findings with global QoL and lung cancer-specific QoL, fatigue and dyspnea were consistent determinants of QoL.ConclusionsWe found four symptoms – dyspnea, fatigue, depression, and sleep difficulties – that are important determinants of and together accounted for almost all of the variance in cancer-specific QoL in lung cancer survivors eligible for long-term cure. These findings have implications to reduce symptom burden and improve function and QoL in these patients.

Lung Cancer ◽  
2012 ◽  
Vol 77 (3) ◽  
pp. 611-616 ◽  
Author(s):  
Lise Solberg Nes ◽  
Heshan Liu ◽  
Christi A. Patten ◽  
Sarah M. Rausch ◽  
Jeff A. Sloan ◽  
...  

Lung Cancer ◽  
2008 ◽  
Vol 61 (1) ◽  
pp. 117-122 ◽  
Author(s):  
Matthew M. Clark ◽  
Paul J. Novotny ◽  
Christi A. Patten ◽  
Sarah M. Rausch ◽  
Yolanda I. Garces ◽  
...  

2011 ◽  
Vol 29 (7_suppl) ◽  
pp. 75-75
Author(s):  
H. C. Quon ◽  
P. Cheung ◽  
D. A. Loblaw ◽  
G. Morton ◽  
E. Szumacher ◽  
...  

75 Background: Combined radiotherapy (RT) and long-term hormonal therapy (HT) is a standard treatment option for high-risk prostate cancer. Dose escalated RT alone has been shown to improve disease free survival. Increased sensitivity of prostate cancer to high doses per fraction has led to hypofractionation as a method to radiobiologically escalate dose.We report on the quality of life of patients treated with combined hypofractionated RT and HT. Methods: A prospective phase I/II study enrolling patients with any of: clinical T3, PSA ≥20, or Gleason 8-10. Forty-five Gy (1.8 Gy/fraction) was delivered to the pelvic nodes with a concomitant 22.5 Gy intensity-modulated RT boost to the prostate, for a total of 67.5 Gy (2.7 Gy/fraction) in 25 fractions over 5 weeks. Hormonal therapy was administered for 2-3 years. Patient reported outcomes were measured at baseline and every 6 months using the validated Expanded Prostate Cancer Index Composite (EPIC) questionnaire, which measures urinary, bowel, sexual, and hormonal domains. Results: Sixty patients with a minimum 24 months of patient-reported outcomes were analyzed. Mean scores comparing baseline to 24 month values are reported. There were no statistically significant changes in the urinary summary scores (86.3 vs. 86.0, p=0.45) or any of the urinary subscales (function, bother, incontinence, irritative/obstructive). Domain summary score decreases were observed in: bowel by 4.4% (94.7 vs. 90.3, p<0.01), sexual by 27% (44.5 vs. 17.5, p<0.01), and hormonal by 11.9% (93.1 vs. 81.2, p<0.01). Examining time trends in outcomes, most changes occurred within the first 6 months with smaller changes thereafter. Conclusions: Hypofractionated RT combined with long-term HT is associated with good patient-reported urinary and bowel outcomes at 24 months. Sexual and hormonal summary scores are affected, largely due to continued androgen deprivation therapy. Further follow-up is needed to document patient reported outcomes after testosterone recovery. No significant financial relationships to disclose.


2012 ◽  
Vol 7 (1) ◽  
pp. 64-70 ◽  
Author(s):  
Ping Yang ◽  
Andrea L. Cheville ◽  
Jason A. Wampfler ◽  
Yolanda I. Garces ◽  
Aminah Jatoi ◽  
...  

2013 ◽  
Vol 17 (suppl 2) ◽  
pp. S132-S132
Author(s):  
I. Ilonen ◽  
V. Rauma ◽  
J. Rasanen ◽  
J. A. Salo

2015 ◽  
Vol 16 (1) ◽  
pp. 40-45 ◽  
Author(s):  
Ville Rauma ◽  
Harri Sintonen ◽  
Jari V. Räsänen ◽  
Jarmo A. Salo ◽  
Ilkka K. Ilonen

Lung Cancer ◽  
2012 ◽  
Vol 77 (1) ◽  
pp. 217-223 ◽  
Author(s):  
Sarah M. Rausch ◽  
Brian D. Gonzalez ◽  
Matthew M. Clark ◽  
Christi Patten ◽  
Sara Felten ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document